Diagnosis of Myasthenia Gravis

Abstract

Myasthenia gravis is an autoimmune disorder of the neuromuscular junction. The diagnosis of myasthenia gravis (MG) is based on clinical features, combined with neurophysiological and immunological parameters. Autoantibodies against the nicotinic acetylcholine receptor are the main finding in about 80% of the patients. More recently, autoantibodies against muscle-specific kinase (MuSK) and lipoprotein receptor-associated protein 4 (LRP4) have been identified in a subset of MG patients. Additionally, anti-titin autoantibodies can point to an underlying thymoma in younger MG patients. Neurophysiological examination includes a repetitive stimulation to detect a possible decrement as the electrical correlate of pathological muscle fatigability. Single-fiber electromyography can identify neuromuscular transmission disturbances in otherwise unclear cases.

Key words

myasthenia gravis - autoantibodies - neurophysiology

• References

• 1 Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handb Clin Neurol 2016; 133: 447-466
• 2 Nielsen FC, Rodgaard A, Djurup R. et al. A triple antibody assay for the quantitation of plasma IgG subclass antibodies to acetylcholine receptors in patients with myasthenia gravis. J Immunol Methods 1985; 83: 249-258
• 3 Toyka KV, Drachman DB, Griffin DE. et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 1977; 296: 125-131
• 4 Vincent A. Autoimmune disorders of the neuromuscular junction. Neurol India 2008; 56: 305-313
• 5 Blaes F, Beeson D, Plested P. et al. IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Ann Neurol 2000; 47: 504-510
• 6 Hoch W, McConville J, Helms S. et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-368
• 7 McConville J, Farrugia ME, Beeson D. et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55: 580-584
• 8 Lavrnic D, Losen M, Vujic A. et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005; 76: 1099-1102
• 9 Lauriola L, Ranelletti F, Maggiano N. et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005; 64: 536-538
• 10 Higuchi O, Hamuro J, Motomura M. et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69: 418-422
• 11 Pevzner A, Schoser B, Peters K. et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259: 427-435
• 12 Cordts I, Bodart N, Hartmann K. et al. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. J Neurol 2017; 264: 1193-1203
• 13 Voltz RD, Albrich WC, Nagele A. et al. Paraneoplastic myasthenia gravis: Detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 1997; 49: 1454-1457
• 14 Szczudlik P, Szyluk B, Lipowska M. et al. Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand 2014; 130: 229-233
• 15 Gasperi C, Melms A, Schoser B. et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology 2014; 82: 1976-1983
• 16 Kimura J. Electrodiagnosis in diseases of nerve and muscle: Principles and practice. Oxford: Oxford University Press; 2001
• 17 Bischoff CS-M, Wilhelm J. Das EMG-Buch. Stuttgart, New York: Thieme; 2010
• 18 Howard Jr. JF. Electrodiagnosis of disorders of neuromuscular transmission. Phys Med Rehabil Clin N Am 2013; 24: 169-192